17. 강병헌, 윤남구, 양수재, 박은선,강수성, "TRAP1 선택적 억제제로서의 화합물 및 이를 포함하는 암 예방 또는 치료용 조성물" 2020. 7. 10. 출원 (출원번호: 제 10-2020-0085681호); 2023.3.27. 등록 (특허번호: 제 10-2516260호).
16. 강병헌 외 8인, "TRAP-1 억제제" 2022. 12. 15. 출원, 대한민국 10-2022-0176017.
15. 강병헌, 윤남구 "TRAP-1 억제제" 2021.06.15. 출원, 대한민국 10-2021-0077327.
14. 강병헌, 김소연, 윤남구 "TRAP-1 억제제의 안과질환 치료 용도" 2021.06.15. 출원, 대한민국 10-2021-0077326.
13. [국제특허/개별국 출원] 강병헌, 김소연, 윤남구, 이창욱, 박동호, "Compound for inhibiting neovascularization and use therof" 2022. 6. 13. 미국 US17/784,969 / 유럽 EP20902617.8 / 호주 AU2020409912 / 일본 JP2022-536658 / 브라질 BR112022011147A / 중국 CN202080090674.9A / 캐나다 CA3164800A / 인도 IN202217036480 / 러시아 RU2022118802
12. Kang BH, Kang SS, Park M, Yun JS, Yang SJ, "Compounds as a TRAP1 selective inhibitor with increased mitochondrial drug accumulation, and use thereof" Feb. 19, 2021, Korea No. 10-2021-0022602.
11. Kang BH, Kim SY, Yun NG, Lee C, Park DH, "Compound for inhibiting neovascularization factor and use thereof" Dec. 16, 2020, Korea No. 10-2020-0176125; PCT No. PCT/KR2020/018475.
10. Kang BH, Kim SY, Yun NG, Lee C, Park DH, "Compound for inhibiting neovascularization factor and use thereof" Dec. 16, 2019, Korea No. 10-2019-0168238.
9. Ryu JH, Kang BH, Thomas AP, Lee AJ, Kim K, "Compound comprising Hsp90 inhibitor targeting mitochondria and pharmaceutical composition for photodynamic therapy comprising the compound" Dec. 28, 2018, Korea No. 10-2018-0173079.
8. Kang, B.H., Park, H.K., et al., "In vivo pan Hsp90 family protein inhibitor Panvotinib-401 as cancer therapeutics" Oct. 26, 2016, Korea No. 10-2016-0140260; Jul. 21, 2017, PCT/KR2017/007907
7. Yun, E.Y., Hwang, J.S., Kang, B.H., Lee, J.E., Jo, D.E., Lee, A.J., Park, H.K. "Composition for protecting liver or for anticancer comprising Allomyrina dichotoma larva as effective component" Jan. 25, 2017, Korea No. 10-1702053 [Registered]
6. Yun, E.Y., Hwang, J.S., Kang, B.H., Lee, J.E., Jo, D.E., Lee, A.J., Park, H.K. "Composition for protecting liver or for anticancer comprising Allomyrina dichotoma larva as effective component" Jan 25, 2017, Korea No. 10-1702046 [Registered].
5. Yun, E.Y., Hwang, J.S., Goo, T.W., Kang, B.H., Lee, J.E., Jo, D.E., Lee, A.J. "Composition for anticancer comprising Protaetia brevitarsis larva or its fraction as effective component" Oct. 8, 2014, Korea No. 10-2014-0135592.
4. Kang, B.H., Lee, C., Ryu, J.H., Park, H.K. "Mitochondria targeted TRAP1 inhibitor SMTIN-P01 as a cancer therapeutics" May 10, 2016, Korea No. 10-1621418 [Registered]
3. Yun, E.Y., Hwang, J.S., Goo, T., Kang, B.H., Lee, J.E. "Composition for anticancer comprising extract of Tenebrio molitor or its fraction as effective components" October 31, 2013, Korea No. 10-2013-0130661.
2. Kang, B.H., Lee, J.E., Park, H.K. "Pharmaceutical composition for treatment of a cancer comprising doxorubicin and gamitinib as active ingredients" Jun 03, 2014, Korea No. 10-1406278 [Registered]
1. Altieri, D.C., Kang, B.H. "Mitochondria-targeted antitumor agents" April 16, 2009, US Publication No. US2009/0099080 A1. [Registered]